Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Gregory Plautz, MD, is Chair of the Department of Pediatric Hemagology-Oncology and Professor of Pediatrics at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He accepted that appointment in 2007. He was previously an Associate Professor and Chief in the Section of Pediatric Hematology/Oncology at Yale University School of Medicine. He began teaching pediatrics at the University of Michigan, a position he held for four years.
His clinical interests include pediatric hematology/oncology, cancer research and immunology.
Dr. Plautz completed his medical degree at Indiana University School of Medicine. He was an intern and resident in pediatrics at Johns Hopkins Hospital. He completed a fellowship in pediatric hematology-oncology at the University of Michigan Medical Center. He holds a Federal DEA license and is licensed to practice medicine in Ohio.
Dr. Plautz is the author or co-author of numerous original peer-reviewed manuscripts, reviews and book chapters. He is a member of the American Society of Hematology, American Association for Cancer Research and International Society for Biological Therapy of Cancer.
cancer research, immunology, pediatric hematology/oncology, childhood cancer, general clinical hematology and oncology, Hodgkin lymphoma, pediatric hematology, pediatric oncology
Awards & Honors
Current Grant Funding
Dendritic cell-brain tumor cell fusion vaccine; Principal Investigator, Gregory E. Plautz, MD; NIH-NCI, RO1 CA120893; 4/07 to 3/12
Aims: 1) To derive BTSC cell lines and autologous DC-tumor fusion cells from patients with GBM, oligoastrocytoma or medulloblastoma. 2) To determine whether active or adoptive immunotherapy induces therapeutic and/or pathologic effects in murine models. 3) To sensitize T cells from brain tumor patients in vitro with DC-BTSC fusion cells and analyze their reactivity against autologous tumor as an approach to adoptive transfer.
Previous Grant Funding
Dendritic cell-GBM fusion cell vaccines; Principal Investigator, Gregory E. Plautz, MD; Brain Tumor Society, 11/1/2006 to 4/1/07
T-cell immunotherapy of pediatric brain tumors; Principal Investigator, Gregory Plautz, MD; 1 RO1 CA91891; 6/1/02 to 5/31/06
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 2/5/2014, Dr. Plautz has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.